The use of covariates and random effects in evaluating predictive biomarkers under a potential outcome framework

Annals of Applied Statistics

Volumn 8, Issue 4, 2014, Pages 2336-2355

  Zhang, Zhiwei ^a   Nie, Lei ^b   Soon, Guoxing ^b   Liu, Aiyi ^c  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Conditional independence; Counterfactual; ROC regression; Sensitivity analysis; Treatment effect heterogeneity; Treatment selection

Indexed keywords

EID: 84919432908     PISSN: 19326157     EISSN: 19417330     Source Type: Journal    
DOI: 10.1214/14-AOAS773     Document Type: Article

References (25)

1. Cohen, C. J., Andrade-Villanueva, J., Clotet, B., Fourie, J., Johnson, M. A., Ruxrungtham, K., Wu, H., Zorrilla, C., Crauwels, H., Rimsky, L. T., Vanveggel, S., Boven, K. and THRIVE STUDY GROUP (2011). Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet 378 229-237.
2. Dodd, L. E. and Pepe, M. S. (2003). Semiparametric regression for the area under the receiver operating characteristic curve. J. Amer. Statist. Assoc. 98 409-417. MR1995717
3. Foster, J. C., Taylor, J. M. G. and Ruberg, S. J. (2011). Subgroup identification from randomized clinical trial data. Stat. Med. 30 2867-2880. MR2844689
4. Gadbury, G. L. and Iyer, H. K. (2000). Unit-treatment interaction and its practical consequences. Biometrics 56 882-885.
5. Gail, M. and Simon, R. (1985). Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41 361-372.
6. Holland, P. W. (1986). Statistics and causal inference (with discussion). J. Amer. Statist. Assoc. 81945-970. MR0867618
7. Huang, Y., Gilbert, P. B. and janes, H. (2012). Assessing treatment-selection markers using a potential outcomes framework. Biometrics 68 687-696. MR3055173
8. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O’callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., Price, T. J., Shepherd, L., Au, H.-J., Langer, C., Moore, M. J. and Zalcberg, J. R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359 1757-1765.
9. Manski, C. F. (2003). Partial Identification of Probability Distributions. Springer, New York. MR2151380
10. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J. and Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen- treated, node-negative breast cancer. N. Engl. J. Med. 351 2817-2826.
11. Pepe, M. S. (2003). The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford Statistical Science Series 28. Oxford Univ. Press, Oxford. MR2260483
12. Pocock, S. J., Assmann, S. E., Enos, L. E. and Kasten, L. E. (2002). Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat. Med. 21 2917-2930.
13. Poulson, R. S., Gadbury, G. L. and Allison, D. B. (2012). Treatment heterogeneity and individual qualitative interaction. Amer. Statist. 66 16-24. MR2934737
14. Qian, M. and Murphy, S. A. (2011). Performance guarantees for individualized treatment rules. Ann. Statist. 39 1180-1210. MR2816351
15. Russek-Cohen, E. and Simon, R. M. (1998). Evaluating treatments when a gender by treatment interaction may exist. Stat. Med. 16 455-464.
16. Simon, R. (2008). Development and validation of biomarker classifiers for treatment selection. J. Statist. Plann. Inference 138 308-320. MR2412589
17. Simon, R. (2010). Clinical trials for predictive medicine: New challenges and paradigms. Clin. Trials 7 516-524.
18. Su, X., Zhou, T., Yan, X., Fan, J. and Yang, S. (2008). Interaction trees with censored survival data. Int. J. Biostat. 4 Art. 2, 28. MR2383729
19. Tian, L., Alizadeh, A. A., Gentles, A. J. and Tibshirani, R. (2012). A simple method for detecting interactions between a treatment and a large number of covariates. Available at arXiv:1212.2995.
20. Van Der Laan, M. J. and Robins, J. M. (2003). Unified Methods for Censored Longitudinal Data and Causality. Springer, New York. MR1958123
21. Zhang, B., Tsiatis, A. A., Laber, E. B. and Davidian, M. (2012). A robust method for estimating optimal treatment regimes. Biometrics 68 1010-1018. MR3040007
22. Zhang, Z., Wang, C., Nie, L. and Soon, G. (2013). Assessing the heterogeneity of treatment effects via potential outcomes of individual patients. J. R. Stat. Soc. Ser. C. Appl. Stat. 62 687-704. MR3118329
23. Zhang, Z., Nie, L., Soon, G. and Liu, A. (2014). Supplement to “The use of covariates and random effects in evaluating predictive biomarkers under a potential outcome framework.” DOI:10.1214/14-AOAS773SUPP.
24. Zhou, X.-H., Obuchowski, N. A. and Mcclish, D. K. (2002). Statistical Methods in Diagnostic Medicine. Wiley, New York. MR1915698
25. Zou, K. H., Liu, A., Bandos, A. I., Ohno-Machado, L. and Rockette, H. E. (2011). Statistical Evaluation of Diagnostic Performance: Topics in ROC Analysis. CRC Press, Boca Raton, FL. MR3052764